SC
AGIO icon

Schubert & Co’s Agios Pharmaceuticals AGIO Stock Holding History

Schubert & Co’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-27
Closed -$621 – 72
2023
Q1 		$621 Sell
27
-3
-10% -$80 ﹤0.01% 1356
2022
Q4 		$842 Hold
30
– – ﹤0.01% 1239
2022
Q3 		$1K Buy
30
+11
+58% +$295 ﹤0.01% 980
2022
Q2 		$0 Buy
19
+16
+533% +$361 ﹤0.01% 1427
2022
Q1 		$0 Buy
3
+1
+50% +$31 ﹤0.01% 1055
2021
Q4 		$0 Buy
+2
New +$81 ﹤0.01% 988

Other funds holding AGIO

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Schubert & Co's AGIO Position: Q2 2023 in Review

Schubert & Co sold out of Agios Pharmaceuticals (AGIO) in Q2 2023, closing a stake of 27 shares — an estimated $621 sold.

Schubert & Co first reported a position in AGIO in Q4 2021 and held it in 6 quarters. The position peaked at $1K in Q3 2022. 152 funds tracked by Wall St. Rank hold AGIO as of Q2 2023.

  • Schubert & Co reported no remaining Agios Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Schubert & Co sold 27 Agios Pharmaceuticals shares in Q2 2023, an estimated $621.
  • Schubert & Co first reported a position in Agios Pharmaceuticals in Q4 2021 and held it in 6 quarters.
  • Schubert & Co's Agios Pharmaceuticals position peaked at $1K in Q3 2022.
  • 152 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q2 2023.

Based on Schubert & Co's 13F filing for Q2 2023, filed 4 Aug 2023.